Oxybutynin Therapy for Urinary Frequency

Introduction to Oxybutynin Therapy

The American Urological Association recommends oxybutynin as second-line therapy for urinary frequency after behavioral interventions have been tried first, with the strength of evidence being Grade B 1, 2, 3

Behavioral interventions, including bladder training, pelvic floor muscle training, fluid management, and caffeine reduction, are mandatory before considering oxybutynin, as they are generally equivalent to or superior to medications for improving frequency and quality of life 1, 2, 3
Weight loss should be implemented if the patient is obese, as even 8% weight loss reduces urinary frequency significantly, according to the American College of Obstetricians and Gynecologists 3, 4

The American Academy of Ophthalmology advises against using oxybutynin in patients with narrow-angle glaucoma unless approved by the treating ophthalmologist 1, 2, 4
The American Gastroenterological Association recommends using oxybutynin with extreme caution in patients with impaired gastric emptying or history of urinary retention 1, 2, 3

The FDA-approved dosing for oxybutynin is 5 mg three times daily, but starting low and titrating up minimizes discontinuation, as recommended by the American College of Clinical Pharmacology 1, 2
Oxybutynin has the highest risk for discontinuation due to adverse effects among all antimuscarinics, with common side effects including dry mouth, constipation, blurred vision, and impaired cognitive function, according to the American Geriatrics Society 6, 4

The European Association of Urology recommends considering alternative antimuscarinics, such as solifenacin, darifenacin, or tolterodine, if oxybutynin causes intolerable side effects, as they have better tolerability profiles 6, 4

The American Urological Association recommends referring patients who fail both behavioral therapy and antimuscarinic therapy to a specialist for consideration of sacral neuromodulation or onabotulinumtoxinA injections 1, 2, 4